NCT06595212 · RECRUITING

Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach

This Italian study is recruiting twins where at least one twin has ALS or frontotemporal dementia (FTD). By comparing the affected twin to their unaffected co-twin, researchers hope to untangle how much genetics versus life experience drives these diseases. It is an observational study, not a drug trial, meaning no treatment is being tested. Details on phase are not specified, so this is a data-collection effort, not a clinical intervention.

You may qualify if

  • Age \>18 yrs
  • Presence of MZ or DZ twins in the family both willing to participate in the study and able to provide informed consent
  • At least one twin is affected by ALS as defined by Gold Coast Criteria (Shefner et al., 2020) and/or by FTD as defined by Strong and colleagues (Strong et al., 2017)
  • Subjects able and willing to comply with study procedures as per protocol
  • Subjects able to understand, and capable of providing informed consent at screening visit before any protocol-specific procedures

You're excluded if

  • Unwillingness to perform assessments as stated in the protocol at least during baseline visit for both twins
  • Unwillingness to donate biological samples collected at periphery (lumbar puncture excluded) for both twins
  • Women who are pregnant or breastfeeding

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-02-04

View full record on ClinicalTrials.gov

All APOE4 clinical trials